TIGIT and neoplasm: Therapeutic resistance to TIGIT blockade can stem from tumor-intrinsic factors, such as low immunogenicity or poor antigen presentation, which limit T cell activation despite TIGIT inhibition (Kalbasi and Ribas, 2020).